Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
Adult
Antiviral Agents
/ adverse effects
Carbamates
Drug Combinations
Drug Therapy, Combination
Genotype
Hepacivirus
/ genetics
Hepatitis C, Chronic
/ complications
Heterocyclic Compounds, 4 or More Rings
/ therapeutic use
Humans
Kidney Failure, Chronic
/ complications
Macrocyclic Compounds
/ therapeutic use
Male
Middle Aged
Prospective Studies
Renal Dialysis
Sofosbuvir
/ therapeutic use
Sulfonamides
/ therapeutic use
Treatment Outcome
chronic kidney disease
directly acting antivirals
hepatitis C virus
renal failure
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
05
09
2020
received:
04
07
2020
accepted:
21
09
2020
pubmed:
8
10
2020
medline:
22
6
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
There is emerging data on the use of Sofosbuvir-based directly acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end-stage renal disease (ESRD) on maintenance haemodialysis (MHD). We evaluated the safety and efficacy of Sofosbuvir plus Velpatasvir fixed-dose combination in CHC patients with ESRD on MHD. Fifty-one CHC patients with ESRD on MHD were included in a real-life prospective study. All patients irrespective of genotype; presence of cirrhosis; treatment naive or experienced status were treated with full-dose Sofosbuvir (400 mg) plus Velpatasvir (100 mg) fixed-dosed combination given daily for 12 weeks. The efficacy was assessed by the sustained virological response (SVR12) with negative HCV RNA 12 weeks after the end of treatment (ETR). Side effects if any were recorded in all patients. The median HCV RNA level in 51 CHC patients [Males 41 (80.4%), mean age 42.8 ± 14.6 years] was 2.0 × 10 Sofosbuvir plus Velpatasvir fixed-dose combination is safe and effective in treating CHC in patients with ESRD on MHD.
Sections du résumé
BACKGROUND & AIMS
There is emerging data on the use of Sofosbuvir-based directly acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end-stage renal disease (ESRD) on maintenance haemodialysis (MHD). We evaluated the safety and efficacy of Sofosbuvir plus Velpatasvir fixed-dose combination in CHC patients with ESRD on MHD.
METHODS
Fifty-one CHC patients with ESRD on MHD were included in a real-life prospective study. All patients irrespective of genotype; presence of cirrhosis; treatment naive or experienced status were treated with full-dose Sofosbuvir (400 mg) plus Velpatasvir (100 mg) fixed-dosed combination given daily for 12 weeks. The efficacy was assessed by the sustained virological response (SVR12) with negative HCV RNA 12 weeks after the end of treatment (ETR). Side effects if any were recorded in all patients.
RESULTS
The median HCV RNA level in 51 CHC patients [Males 41 (80.4%), mean age 42.8 ± 14.6 years] was 2.0 × 10
CONCLUSION
Sofosbuvir plus Velpatasvir fixed-dose combination is safe and effective in treating CHC in patients with ESRD on MHD.
Substances chimiques
Antiviral Agents
0
Carbamates
0
Drug Combinations
0
Heterocyclic Compounds, 4 or More Rings
0
Macrocyclic Compounds
0
Sulfonamides
0
velpatasvir
KCU0C7RS7Z
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-709Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;95(4):939-947.
Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127-134.
Jasuja S, Gupta AK, Choudhry R, et al. Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol. 2009;19(2):62-67.
Constancio NS, Ferraz MLG, Martins CTB, Kraychete AC, Bitencourt PL, Nascimento MMD. Hepatitis C in hemodialysis units: diagnosis and therapeutic approach. J Bras Nefrol. 2019;41(4):539-549.
Fabrizi F, Dixit V, Messa P. Hepatitis C virus and mortality among patients on dialysis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019;43(3):244-254.
Kesiraju S, Srikanti P, Sahariah S. Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends. Virusdisease. 2017;28(3):233-241.
Pedroso S, Martins L, Fonseca I, et al. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplant Proc. 2006;38(6):1890-1894.
Hepatitis C. Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477-1492.
Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448-1455.
Puri P, Saraswat VA, Dhiman RK, et al. Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: update 2016. J Clin Exp Hepatol. 2016;6(2):119-145.
Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016;39(7):589-611.
Taneja S, Duseja A, De A, et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63(5):1334-1340.
Kalyan Ram B, Frank C, Adam P, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63(3):763-765.
Goel A, Bhadauria DS, Kaul A, et al. Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology. 2019;24(3):316-321.
Singh A, Kumari S, Kumar P, De A, Singh V. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency. J Viral Hepat. 2018;25(12):1501-1506.
Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71(4):660-665.
Gaur N, Malhotra V, Agrawal D, et al. Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. J Clin Exp Hepatol. 2020;10(3):189-193.
Taneja S, Tohra S, Duseja A, Dhiman RK, Chawla YK. Noninvasive assessment of liver fibrosis by transient elastography and FIB4/APRI for prediction of treatment response in chronic hepatitis C-an experience from a Tertiary Care Hospital. J Clin Exp Hepatol. 2016;6(4):282-290.
Taneja S, Borkakoty A, Rathi S, et al. Assessment of liver fibrosis by transient elastography should be done after hemodialysis in end stage renal disease patients with liver disease. Dig Dis Sci. 2017;62(11):3186-3192.
Pyne MT, Mallory M, Hillyard DR. HCV RNA measurement in samples with diverse genotypes using versions 1 and 2 of the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV test. J Clin Virol. 2015;65:54-57.
Cottone C, Bhamidimarri KR. Evaluating CKD/ESRD patient with hepatitis C infection: how to interpret diagnostic testing and assess liver injury. Semin Dial. 2019;32(2):119-126.
Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease. Hemodial Int. 2018;22(3):297-307.
Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15(2):73-86.
Davis MI, Chute DF, Chung RT, Sise ME. When and how can nephrologists treat hepatitis C virus infection in dialysis patients? Semin Dial. 2018;31(1):26-36.
Angulo-Diaz V, Lim JK, Martin P, Liapakis A. Management of chronic hepatitis C in end-stage renal disease. J Clin Gastroenterol. 2018;52(4):287-294.
Lee CH, Hsieh SY, Chang CC, et al. Hepatocellular carcinoma in hemodialysis patients. Oncotarget. 2017;8(42):73154-73161.
Isnard Bagnis C, Cacoub P. Hepatitis C therapy in renal patients: who, how, when? Infect Dis Ther. 2016;5(3):313-327.
Kanda T, Lau GKK, Wei L, et al. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019;13:103-109.
Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10(12):1363-1377.
Taneja S, Duseja A, De A, et al. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Nephrology. 2018;23(9):876-882.
Manoj K, Nayak SL, Gupta E, Kataria A, Sarin SK. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver Int. 2018;38(12):2137-2148.
Sood A, Duseja A, Kabrawala M, et al. Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatol Int. 2019;13(2):173-179.